Germline and somatic multi-gene sequencing in patients (pts) with advanced high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC)

Germline and somatic multi-gene sequencing in patients (pts) with advanced high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC)

Conclusions: Comprehensive germline and tumor analysis with 52 gene panel in advanced HGSOC and TNBC found previously unidentified GPV in 9% of pts and somatic mutations in HR genes in 14% of germline WT pts. This increases options for targeted therapeutics with investigational agents, such as PARP inhibitors. 

GPV = germline pathogenic variants